AxoGen (AXGN) Surges 7.5%: Is This an Indication of Further Gains?

AAPL TSLA AMZN META AMD NVDA PEP COST ADBE GOOG AMGN HON INTC INTU NFLX ADP SBUX MRNA AAPL TSLA AMZN META AMD NVDA PEP COST ADBE GOOG AMGN HON INTC INTU NFLX ADP SBUX MRNA AAPL TSLA AMZN META AMD NVDA PEP COST ADBE GOOG AMGN HON INTC INTU NFLX ADP SBUX MRNA Stocks AxoGen (AXGN) Surges 7.5%: Is This an Indication of Further Gains? April 17, 2026 — 06:57 am EDT Written by Zacks Equity Research for Zacks-> AxoGen AXGN shares soared 7.5% in the last trading session to close at $37.37. The move was backed by solid volume with far more shares changing hands than in a normal session. This compares to the stock's 12.4% gain over the past four weeks.AxoGen scored a strong price increase on investors’ optimism surrounding the company’s impending first quarter 2026 financial results, which is slated to release on April 28. Per the Zacks Consensus Estimate, the company’s revenues are expected to increase 20.9% year over year. Earnings per share is pegged at 11 cents for the first quarter, indicating a huge 650% year over year improvement. This regenerative medicine company is expected to post quarterly earnings of $0.11 per share in its upcoming report, which represents a year-over-year change of +650%. Revenues are expected to be $58.7 million, up 20.9% from the year-ago quarter.While earnings and revenue growth expectations are important in evaluating the potential strength in a stock, empirical research shows a strong correlation between trends in earnings estimate revisions and near-term stock price movements.For AxoGen, the consensus EPS estimate for the quarter has been revised 200% lower over the last 30 days to the current level. And a negative trend in earnings estimate revisions doesn't usually translate into price appreciation. So, make sure to keep an eye on AXGN going forward to see if this recent jump can turn into more strength down the road.The stock currently carries a Zacks Rank #3 (Hold). You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>>AxoGen is part of the Zacks Medical - Instruments industry. LivaNova LIVN, another stock in the same industry, closed the last trading session 0.2% lower at $65.01. LIVN has returned 3.7% in the past month.LivaNova's consensus EPS estimate for the upcoming report has remained unchanged over the past month at $0.85. Compared to the company's year-ago EPS, this represents a change of -3.4%. LivaNova currently boasts a Zacks Rank of #2 (Buy). #1 Semiconductor Stock to Buy (Not NVDA) The incredible demand for data is fueling the market's next digital gold rush. As data centers continue to be built and constantly upgraded, the companies that provide the hardware for these behemoths will become the NVIDIAs of tomorrow. One under-the-radar chipmaker is uniquely positioned to take advantage of the next growth stage of this market. It specializes in semiconductor products that titans like NVIDIA don't build. It's just beginning to enter the spotlight, which is exactly where you want to be.See This Stock Now for Free >>Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free reportAxoGen, Inc. (AXGN) : Free Stock Analysis ReportLivaNova PLC (LIVN) : Free Stock Analysis ReportThis article originally published on Zacks Investment Research (zacks.com).Zacks Investment Research The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

Tags Stocks Zacks Zacks is the leading investment research firm focusing on stock research, analysis and recommendations. In 1978, our founder discovered the power of earnings estimate revisions to enable profitable investment decisions. Today, that discovery is still the heart of the Zacks Rank. A wealth of resources for individual investors is available at www.zacks.com. More articles by this source-> Stocks mentioned AXGN LIVN More Related Articles This data feed is not available at this time. Data is currently not available • Sign up for the TradeTalks newsletter to receive your weekly dose of trading news, trends and education. Delivered Wednesdays.